Verona Pharma plc (I9SA) — Long-term Investment Intensity
Verona Pharma plc (I9SA) has a Long-term Investment Intensity of 2.6% as of June 2025. Long-term investments of €15.00 Million represent 2.6% of total assets of €572.87 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Verona Pharma plc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Verona Pharma plc Long-term Investment Intensity (2021–2024)
This chart shows how Verona Pharma plc's Long-term Investment Intensity has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the intensity stands at 2.6%, reflecting long-term investments of €15.00 Million against total assets of €572.87 Million EUR. Explore I9SA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Verona Pharma plc (2021–2024)
The table below presents the year-by-year Long-term Investment Intensity for Verona Pharma plc from 2021 to 2024, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see I9SA stock market capitalisation.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 3.2% | €15.00 Million | €474.24 Million | ▼ -1.7 pp |
| 2023 | 4.9% | €15.00 Million | €308.12 Million | ▼ -0.9 pp |
| 2022 | 5.8% | €15.00 Million | €259.47 Million | ▼ -2.3 pp |
| 2021 | 8.0% | €15.00 Million | €186.59 Million | — |